Key facts
- Sanoptis’s last known valuation is $1.7B (Apr 2022).
- It has raised $268.2M; the latest was PE Growth/Expansion ($268.2M) in Mar 2025.
- Notable investors include The Carlyle Group, Groupe Bruxelles Lambert.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sanoptis
- ·The full record, as it builds
Funding rounds
No funding rounds for Sanoptis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sanoptis
Operator of a network of modern ophthalmology clinics intended to partner with ophthalmologists to deliver on organic and inorganic growth. The company specializes in covering a range of diagnostic and surgical treatments including cataract operations and intravitreal injections for age-related macular degeneration through its hospitals and outgoing facilities, ensuring its patients get reliable treatment to improve their well-being and quality of life effectively.
- Sector
- Healthcare
- HQ
- Zug, Switzerland
- Founded
- 2018
- Employees
- 4,700
- Website
- sanoptis.com/
- Ownership
- Privately Held (backing)
Sanoptis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sanoptis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sanoptis in its N-PORT filings yet. We sweep new filings monthly.